Table of Contents Table of Contents
Previous Page  502 / 671 Next Page
Information
Show Menu
Previous Page 502 / 671 Next Page
Page Background

SUMMARY 2

MSCC

RS / SBRT conv.

RT

Improvement, less selected:

23%

40%

Improvement, myeloma:

71%

76%

Improvement, ambulatory:

63%

62%

Potential Benefit of RS / SBRT for:

Long-term Survivors (SBRT instead of RS to reduce late

toxicity)

Less Radiosensitive Tumors

Re-RT, in particular after previous longer-course RT